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SLEDAIAbstract Background: Systemic lupus erythematosus (SLE) is characterized by a vicious cycle
maintaining systemic inﬂammation. It starts by autoantibody production, immune complex
formation and complement activation that contribute to inﬂammation, tissue damage and further
autoantibody production.
Aim of the work: To evaluate the association between the auto-antibodies (abs), circulating
immune complexes (CIC), and complement activity in SLE patients.
Patients and methods: This study involved 30 female SLE patients analyzed for autoantibodies,
complement proﬁle including complement hemolytic 50 (CH50), alternative pathway 50, factor B,
C1q, C2, C3 and C4 as well as C1q-CIC. SLE disease activity was assessed by the SLE Disease
Activity Index (SLEDAI).
Results: The age of patients was 34 ± 12.8 years, disease duration was 5.2 ± 3.2 years and their
mean SLEDAI was 9.96 ± 4.2. Anti-SSA, anti-dsDNA, anti-C1q abs, and CIC were detected in
36.7%, 50%, 50% and 30% of patients, respectively. Anti-SSA were higher in patients with lower
compared to normal CH50 activity and C3 level (24.7 vs 88.6 U/ml; p= 0.002 and 118.6 ± 25.18
U/ml vs 15.9 ± 7.3; p< 0.0001 respectively) than the other autoantibodies. Increased CIC were
higher in patients with lupus nephritis and were associated with anti-SSA, anti-SSB, anti-C1q,
anti-Sm and in patients with low CH50 activity. The CIC signiﬁcantly correlated with anti-C1q
(r= 0.69, p< 0.0001), anti-SSA (r= 0.5, p= 0.005) and negatively with CH50 (r= 0.4,
p= 0.046).
Conclusions: The current study conﬁrms that the etiopathogenic anti-SSA autoantibodies are the
most associated with hypocomplementemia in SLE. This would stimulate future researches for
172 K. Kerboua et al.validation of predictive biomarkers earlier than hypocomplementemia which is still the major
unmet need in lupus research and patient care.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease
characterized by disturbed tolerance to self antigens and devel-
opment of auto-antibodies leading to the formation of immune
complexes (ICs) [1]. These ICs deposit in the tissues initiating
an immune response by activating the complement cascade
and recruiting inﬂammatory cells [2]. The etiology of SLE is
still not fully understood but the autoantibodies [3] and inter-
play of multiple factors including cytokine over production
[4,5] and genetic predisposition [6] have been involved in the
abnormal immune responses and pathogenesis of SLE.
Furthermore, apoptosis [7] and oxidative stress [8] play central
roles in the development of the disease.
Ro60 (also called 60 kDa SS-A) is an RNA-binding protein
of 60 kDa that takes its name from the initials of a systemic
lupus erythematosus (SLE) patient ‘‘Ro” [9] and the other
nomenclature related to its association with Sjo¨gren’s syn-
drome (SS) [10]. It is proposed to function in a clearance path-
way in which imperfect noncoding RNAs are targeted for
decay, for cell survival; and ultimately, prevention of autoim-
munity [11]. In autoimmune rheumatic disorders, among a
variety of autoantibodies, the Ro/SSA abs are the most preva-
lent extractable nuclear antigen (ENA) speciﬁcity identiﬁed in
laboratories. Sera from SLE patients have anti Ro antibodies
(abs) in 24–60% and in 70–100% of patients with subacute
cutaneous lupus erythematosus [12,13].
Needless to a reminder that releasing high amount of auto-
abs is followed by intensive consumption of the classical
complement compounds [14]. This latter is considered the best
predictive biomarker for SLE ﬂare and is included in SLE
diagnosis criteria [15]. Hence, it is vital to detect an antibody
that would be associated the most with hypocomplementemia
to detect earlier SLE ﬂare and help to monitor SLE activity. In
this way, McClain and colleagues have taken an important
step in answering these questions by determining that anti
SSA auto-abs appeared nearly 4 years before the diagnosis of
lupus [16].
The aim of this study was to evaluate serum autoantibodies
with special attention to anti-Ro/SSA abs and assess their
relation to hypocomplementemia and circulating immune
complexes (CIC) in Algerian SLE patients.
2. Patients and methods
This study involved 30 consecutive female SLE patients
attending different wards of the Central Military University
Hospital, Algiers, Algeria. All patients fulﬁlled the 1997
American College of Rheumatology (ACR) criteria [17]. The
SLE Disease Activity Index (SLEDAI) was done for each
patient [18]. The absence of ﬂare was deﬁned by SLEDAI = 0
after subtraction of anti-double stranded deoxyribonucleic
acid (anti-dsDNA) and complement points from SLEDAIindex. All patients gave written informed consent, and the
study protocol was fully approved by the ethics committee of
the Central Military University Hospital, Algiers, Algeria.
The plasma and sera were separated and stored at 80 C until
analysis of the autoantibodies and complement as well as the
CIC.
2.1. Autoantibodies and CIC analysis
Antinuclear antibodies (ANA) were detected by indirect
immunoﬂuorescence (IIF) using the HEp-2000 test (BioRad,
Germany). Titers equal or exceeding 1:160 were considered
positive. Qualitative estimation of autoantibodies against 12
antigens: ribonucleoprotein (RNP), Smith (Sm), SS-A, SS-B,
Tripartite Motif Containing 21 (TRIM21), scleroderma-70
(Scl-70), polymyositis-scleroderma (PM-Scl), Jo-1, centromere
B, Proliferating cell nuclear antigen (PCNA), ds-DNA, nucle-
osome, histone and ribosomal protein P by bead cytometry
Luminex (Austin, Texas, USA) using FIDISTM connective 10
FIDIS (Biomedical diagnostics, ‘BMD’, Belgium). Three dif-
ferent assays were used to quantify anti-dsDNA: IIF by
Crithedia lucilaea (Bio-RAD), ELISA (BioSystems, Spain)
and Luminex. ELISA was used for anti-nucleosome
(BioSystems, Spain), anti-phospholipids [IgG, IgM anti-
Cardiolipin and anti B2GPI] (VARELIS), anti histones abs
(EUROIMMUN, Germany), and to quantify C1q-CIC
(BINDAZYMETM CIC Human Anti-C1q). Normal values
were considered according to the manufacturer’s instructions:
anti ds-DNA abs (P50 UI/ml by ELISA and P40 UI/ml by
Luminex), anti-nucleosome abs (P10 AU/ml), anti C1q abs
(P20 AU), CIC (P10.8 lg Eq) and for anti histone abs
(P20 U).
2.2. Complement analysis
The classical and alternative complement pathways hemolytic
activities were assessed by the previously described CH50 and
AH50 [19]. Antigenic C1q, C2 and complement factor B
(CfB) were assayed by radial immunudiffusion (The Binding
Site Birmingham, UK), while light-scatter techniques neph-
elometry was used for C3 and C4 (nephelometry on BN
Prospec by Siemens). Detection of anti-C1q Abs (IgG) was
performed by ELISA with puriﬁed C1q (The Binding Site,
Birmingham, UK).
2.3. Statistical analysis
Correlations between complement parameters, C1q-CIC, and
auto-abs were done by the nonparametric Spearman’s Rank.
Non-parametrical Mann–Whitney U test was used for analysis
of statistical relations between patient groups and immunolog-
ical markers. Results were considered signiﬁcant when
p< 0.05. Statistical analysis was performed using SPSS for
Table 3 Autoantibodies, complement proﬁle and circulating
immune complexes (CIC) in SLE patients.
Test SLE patients (n= 30)
+ve ﬁnding (%) Cutoﬀ
Autoantibodies
ANA (IIF) positivity 73.3 1:160
Anti-dsDNA
IIF positivity 30 1:10
ELISA (IU/ml) 46.7 50
Luminex (IU/ml) 50 40
Anti-C1q (U/ml) 50 20
Anti-nucleosome (U/ml) 86.7 10
Anti-histone (U/ml) 20 20
Anti SSA 60 (U/ml) 36.7 40
Anti SSB (U/ml) 16.7 40
Anti Sm (U/ml) 6.7 40
Anti U-RNP (U/ml) 16.7 40
Anti centromere (U/ml) 0 40
Anti Jo1 (U/ml) 0 40
Anti TRIM21 (U/ml) 33.3 40
Anti PLs IgG (GPL) 16.7 10
IgM (MPL) 10
Complement components
CH50 (U) 7.9 80% NP
C1q (mg/dl) 7.9 80% NP
C2 (mg/dl) 13.2 80% NP
C3c (mg/dl) 7.9
C4 (mg/dl) 15.8
AP50 (U) 7.9 80% NP
C fB (mg/dl) 7.9 80% NP
Circulating immune complexes
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USA).
3. Results
The mean age of 30 patients was 34 ± 12.8 years, the mean
disease duration was 5.2 ± 3.2 year their mean SLEDAI was
9.96 ± 4.2 (Table 1). Regarding ACR criteria for SLE, arthri-
tis was detected in more than 80% of patients, followed by
photosensitivity and hematological disorders. The frequency
of ANA was 73.3%. The clinical features of the studied
patients did not differ from the ACR one (Table 2).
The current study exhibited high frequencies for anti-
nucleosome, anti ds-DNA and anti C1q abs. Anti nuclear
abs were positives in 72.2%. For the ENAs; anti Sm, anti
U1-RNP, anti SSA60 and anti SSB were positives at 6.7%,
16.7%, 36.7%, 16.7% respectively. There were no positive sera
for anti centromere-B or anti Jo1 abs. Otherwise, for the non-
ENAs: the frequency for anti histones was 20% and 86.7% for
anti nucleosome, while anti ds-DNA was found in 30% by IIF,
46.7% by ELISA and 50% by Luminex. The frequency of pos-
itive antiphospholipid abs was totally 16.7% and CH50 activity
was decreased in 80% of SLE patients (Table 3).
None of the anti-SSA positive patients had any known
homozygous deﬁciency for C2 or C4. Among the auto-
immunity panel, only anti-dsDNA assessed by Luminex and
anti-SSA abs were associated with complement consumption.
Anti-SSA were higher in patients with lower CH50 and C3
(24.7 vs 88.6 U/ml; p= 0.002 and 118.6 ± 25.18 U/ml vs
15.9 ± 7.3; p< 0.0001 respectively). Of interest, there wasTable 1 Age, disease duration, number of ACR criteria and
disease activity in SLE patients.
Characteristics Mean ± SD
Age (years) 34 ± 12.77
Disease duration (years) 5.22 ± 3.18
ACR criteria (n) 6.66 ± 2.39
SLEDAI 9.96 ± 4.2
Renal SLEDAI 2.086 ± 1.3
ACR: American college of rheumatology, SLEDAI: systemic lupus
erythematosus disease activity index.
Table 2 Clinical features according to the ACR criteria for
SLE in the patients.
SLE criteria n %
Skin lesions 21 (70)
Discoid rash 11 (36.7)
Photosensitivity 23 (76.7)
Oral ulcers 14 (46.7)
Arthritis 25 (83.3)
Serositis 17 (56.7)
Renal involvement 13 (43.3)
Neurological disorders 6 (20)
Hematological disorders 23 (76.7)
Antinuclear antibodies 22 (73.3)
ACR: American college of rheumatology, SLE: systemic lupus
erythematosus.
C1q-CIC (lg Eq/ml) 30 4.4–10.8
SLE; systemic lupus erythematosus, ANA: antinuclear antibodies,
IIF: indirect immunoﬂuorescence, ELISA: enzyme linked
immunosorbent assay, SS: Sjo¨gren syndrome, Sm: Smith, RNP:
ribonucleoprotein, TRIM: Tripartite Motif Containing 21, PLs:
phospholipids, Ig: immunoglobulins, CH50: complement hemolytic
50, C; Complement, AP: alternative pathway, C fB: complement
factor B, CIC: circulating immune complexes, NP: normal
population.no signiﬁcant difference in the detection of anti-dsDNA in
patients’ sera with low and normal C3 (529.6 ± 175.5 IU/ml
vs 463.5 ± 53.9 IU/ml, p= 0.1), although the values differed
signiﬁcantly between those with low and normal CH50 (874
± 430.48 UI/ml vs 137 ± 39.38 UI/ml, p= 0.000) (Fig. 1).
Increased C1q-CIC levels were higher in patients with lupus
nephritis (14.8 ± 4.9 lg Eq/ml vs 4.99 ± 0.9 lg Eq/ml;
p= 0.03) and were associated with anti-SSA 60 kDa (15.4
± 5.4 lg Eq/ml vs 5.7 ± 1.5 lg Eq/ml; p= 0.04), anti-SSB
(25 ± 10.4 vs 6.1 ± 1.3; p= 0.001), anti-C1q (13.9
± 3.6 lg Eq/ml vs 3.1 ± 0.9 lg Eq/ml; p= 0.02), anti-Sm
(21.5 ± 9.2 lg Eq/ml vs 7.4 ± 2.1 lg Eq/ml; p= 0.04) and in
patients with low CH50 activity (36.8 ± 12.8 lg Eq/ml vs
6.18 ± 1.27; p< 0.0001) (Fig. 2). The CIC-C1q level signiﬁ-
cantly correlated with the anti-C1q and anti-SSA 60 kDa abs
and negatively with the CH50 (Table 4).
4. Discussion
A conserved RNA-binding protein, the Ro 60 kDa (Ro60)
auto-antigen, is a major target of autoantibodies in patients
Figure 1 Anti ds-DNA and anti-SSA according to low and normal C3 and CH50 levels in SLE patients. * = signiﬁcant at p< 0.05,
** = signiﬁcant at p< 0.001. CH50: complement hemolytic 50, C: complement, NS: not signiﬁcant.
Figure 2 The circulating immune complex (CIC) titers according to the presence of lupus nephritis, low CH50 activity and
autoantibodies. * = signiﬁcant at p< 0.05, ** = signiﬁcant at p< 0.001. CH50: complement hemolytic 50, C: complement, Sm: Smith,
SS: Sjo¨gren syndrome.
Table 4 CIC titer correlations with anti-SSA, anti-C1q
antibodies and CH50 in SLE patients.
Parameters r (p) CIC
Anti-SSA 0.5 (0.005)
Anti-C1q 0.69 (<0.0001)
CH50 0.4 (0.046)
SS: Sjo¨gren syndrome, CIC: circulating immune complexes, CH50:
complement hemolytic 50.
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acute cutaneous lupus erythematosus and neonatal lupus ery-
thematosus. This protein binds misfolded noncoding RNAsin vertebrate cells and likely functions in a pathway by which
defective RNAs are recognized and targeted for degradation
[20]. Besides, SLE is known for its high apoptotic cell load;
and consequently, the extensive exposition of SSA may induce
anti-SSA abs and autoimmunity. Otherwise, the pathogenesis
of active SLE involved reduced serum complement with abun-
dant CIC levels [21]. Therefore, the immune complex theory
postulated that immune complexes of autoantibodies and their
related auto-antigens activate complement, resulting in com-
plement consumption and tissue damage. Moreover, possible
roles for complement proteins, particularly C1q in the regula-
tion of cytokine release have also been suggested in SLE which
drew more attention for anti-C1q involvement in this disease
[22,23]. Given these observations, it has been proposed that
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activity are of high interest and the current study was designed
to investigate their association.
The present results revealed that CH50 activity is decreased
in about 80% of SLE patients. Nonetheless, only anti-dsDNA
and anti-SSA were associated with hypocomplementemia.
However, anti-SSA abs levels were signiﬁcantly increased in
C3low sera, which is in disagreement with the results obtained
by Mok et al. who have shown that the serum levels of anti-
dsDNA abs correlated negatively with C3 and C4 levels [24].
A variety of tests that can detect anti-dsDNA abs have been
described and only a few of them exhibit a reliable clinical
and scientiﬁc usefulness. The current study conﬁrmed that
anti-dsDNA abs assessed by Luminex (not by ELISA or
IIF), were associated with hypocomplementemia. Of note,
anti-dsDNA abs, albeit they have less speciﬁcity, are the most
sensitive for SLE. They are found in the sera of 55% to 80%
SLE patients, which concords with our results.
As in our study (36.7%), anti-Ro 60 abs are the second
most frequent SLE associated auto-abs [25,26]. Both classi-
cally complement function and the occurrence of anti-SSA
inﬂuenced circulating IC levels, with a strong relation between
decreased complement function and the occurrence of anti-
SSA abs [27]. In contrast to the study of Hassan et al. [27],
the levels of anti-SSA exhibit variations in relation to low
C3, low CH50 and correlate signiﬁcantly with CICs. This is
in accordance with another study showing higher signiﬁcance
[28]. Furthermore, cytoplasmic (Ro) antigens could be
involved in immune complexes [1,29] and are capable of ﬁxing
the complement [1]. This latter is employed clinically as an
indirect and early indicator of the presence of immune-
complex-mediated tissue damage, as well as a useful guide
for the suppression of disease activity by immunosuppressive
agents.
Impairment of IC handling is believed to be pathogenic and
relevant to the complement system in SLE patients [30].
Nevertheless, these data don’t follow the previous studies
about the tendency of anti SSA60 to mediate antibody depen-
dent cellular cytotoxicity (ADCC)-induced damage, because
the most cogent explanation for this hypocomplementemia is
the complement dependant cytotoxicity (CDC). In other
words, immune complexes consist of antibodies associated
with their corresponding antigens to provoke type III hyper-
sensitivity that involves the classic complement pathway [31].
Noteworthy, persistent IC induce the production of IL10
and IL6 that might contribute to increased speciﬁc production
of anti-SSA, further IC production, and thereby contribute to
a vicious cycle in SLE maintaining systemic inﬂammation [1].
None of the anti-SSA positive patients had any known
homozygous deﬁciency for C2 or C4 as this could have caused
a bias in the analysis.
In accordance to previous studies (30–60%) [32,33], the cur-
rent study found an autoimmune response directed to C1q in
50% of SLE patients. Besides, our results show that serum anti
C1q antibodies levels correlated with serum C1q-CIC concen-
trations. After Eugenia Ba˘la˘nescu et al. this positive correla-
tion could be explained by the fact that decreased CIC
binding to erythrocytes and platelets may increase their serum
half-life [34]. It is possible that CIC binding of C1q determines
C1q conformational changes similar with those described
when binding to cryoglobulins [35]. Moreover, we found that
CIC was signiﬁcantly associated with low CH50 and correlatednegatively with it, which is in accordance with previous data
showing the important role of complement, in particular C3,
in the clearance of ICs [36]. Small CIC are common activators
of the classic pathway that cause generally hypocomple-
mentemia, the hallmark of SLE. Abnormal clearance of these
complexes was suggested to play a major etiologic inﬂuence in
SLE [37]. Removal failure, possibly related to abnormalities in
the interaction of these apoptotic bodies with classic pathway
components may sustain the presence of CIC within tissues
and potentially evoke an autoimmune response that may tar-
get C1q thus amplifying this process [38,39].
Anti-SSA antibodies are regarded as earlier SLE markers,
but have not previously been associated with disease activity.
The results of the present study indicate that these antibodies
might be of importance in the formation of CIC and hypocom-
plementemia. The current data suggest that the measurement
of anti-SSA abs may be a helpful tool in the assessment of
patients with biologically active SLE. Of note, anti dsDNA
may be used to monitor SLE activity, albeit it depends on
the methods variability and availability. Hereby, only anti
dsDNA assessed by Luminex was associated with hypocom-
plementemia. Conducting the study longitudinally and on a
larger scale is recommended to conﬁrm our results and study
the possible relations with other autoantibodies, relation to
medications and disease damage.Conflict of interest
None.
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